| Overview |
| bs-2621R-Cy3 |
| IL-21 Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse |
| Rat, Dog, Cow, Pig |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human IL-21 |
| 65-155/155 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 59067 |
| Q9HBE4 |
| Secreted |
| Za11; IL-21; CVID11; Interleukin-21; IL21 |
| Cytokine with immunoregulatory activity. May promote the transition between innate and adaptive immunity. Induces the production of IgG(1) and IgG(3) in B-cells (By similarity). May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells. During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz